Nanobiosensors for Leukemia Minimal Residual Disease Monitoring: A Review of Recent Advances and Translational Challenges
Nanobiosensors can detect leukemia relapse at far lower levels than current methods, though substantial work remains before clinical use.
This review of nanobiosensor technology for leukemia MRD monitoring highlights platforms achieving femtomolar detection sensitivity for clinically relevant MRD markers including ctDNA, fusion gene transcripts, and extracellular vesicles, which outperform conventional flow cytometry and qPCR threshold. However, the authors identify critical translation barriers including insufficient standardization, cross-platform comparability, and regulatory readiness that must be addressed before clinical deployment.
What the study was
- Study design
- narrative_review
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- ACS Sens
Why it surfaced
Comprehensive mapping of nanobiosensor MRD technology landscape with structured translational framework; ACS Sensors publication; relevant to leukemia monitoring pipeline but primarily preclinical/review content limits immediate clinical impact.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.